Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mycobacterium mutants for vaccines with improved protective efficacy

A technology of mycobacterium, Mycobacterium bovis, applied in the field of vaccines

Inactive Publication Date: 2012-11-14
VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +2
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Vaccines with attenuated M. tuberculosis also have potential safety concerns and special care must be taken (eg, double mutations, each single mutation resulting in sufficient attenuation) (Kamath et al., 2005; Walker et al., 2010)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycobacterium mutants for vaccines with improved protective efficacy
  • Mycobacterium mutants for vaccines with improved protective efficacy
  • Mycobacterium mutants for vaccines with improved protective efficacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0153] Example 1. Production and Screening of Mycobacterium bovis BCG Mutants

[0154] Transmission of transposons by fungal phage is an efficient method for generating mycobacterial saturation mutagenesis libraries (54). This method makes it possible to generate multiple mutants in an isogenic background suitable for comparing the effects of different genetic mutations. Insertion of transposons into genes most often results in their inactivation, and reverting frequencies are usually very low (47). Transposons can also be used to deliver other markers, such as antibiotic resistance genes. It also allows transposons to flank genomic regions to be amplified and identified by sequencing (27). Transposon mutagenesis has been successfully used in both fast-growing and slow-growing strains of mycobacteria (1, 10, 32, 51). Here, we generated a library of 96 × 96 clones of ordered M. bovis BCG transposon insertion mutants using Himar1-derived minitransposons (49) delivered by temp...

Embodiment 2

[0160] Example 2. Biochemical characterization of transposon insertion mutants

[0161] Southern analysis to confirm single transposon insertion

[0162]The presence of single transposon insertions in the genome was confirmed by further characterizing the sequence-confirmed mutants by Southern blotting probed with the full-length transposon. This is essential in order to ensure that the observed mutant phenotype is caused by a transposon insertion that results in the individual inactivation of the gene of interest. Except for three mutants ( figure 2 Except for A), all other mutants show single transposon insertions.

[0163] Mutants in Mb1661c, Mb2203, Mb2196 and SapM

[0164] In our library screening we obtained 2 mutants each for the genes Mb1661c, Mb2203 and Mb2196. One of the mutants of genes Mb2203 and Mb2196 showed multiple transposon insertions when analyzed by Southern blot analysis and was removed from further use. Of the two mutants of the gene Mb1661c, we dec...

Embodiment 3

[0184] Example 3. Mycobacterium bovis BCG wild-type to mutant SapM::T (Mb3338::T), Mb2203::T, Mb1661c::T and Mb2196::T in BALB / c mouse protective efficacy

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is Mycobacterium bovis Bacille Calmette-Guerin (M. bovis BCG). In the present invention, mutation of mycobacterial components reportedly involved in phagosome maturation inhibition was evaluated for vaccine purposes, as such mutations should result in better vaccine antigen processing and presentation. Thus, BCG mutants in genes coding for ManLAM capping a-1,2-mannosyltransferases and the PI3P phosphatase SapM were evaluated as TB vaccines in a stringent mouse model. Vaccination with both ManLAM capping mutants and the SapM mutant resulted in significantly longer survival as compared to non-vaccinated mice, whereas vaccination with the parental BCG did not. Moreover, mice vaccinated with the SapM mutant survived significantly longer than mice vaccinated with the parental BCG.; The mutant BCG strains showed unaltered phagocytosis, replication, lysosome colocalization and oxidant activity in macrophages and similarly induced autophagy in the latter. Additionally, replication and granuloma formation in mice was unaffected, indicating BCG-equivalent safety of these vaccines.

Description

technical field [0001] The present invention relates to the field of vaccines, most particularly vaccines based on live attenuated Mycobacterium. Disclosed herein are genes which, when mutated in mycobacteria used to immunize animals, especially mammals, confer improved protective efficacy as vaccines against Mycobacterium infections without interfering with bacteria such as Mycobacterium bovis Beneficial properties of known inoculum strains of Mycobacterium bovis BCG. Such vaccines are especially suitable for Mycobacterium tuberculosis infection. Background technique [0002] One third of the world's population is infected with the TB pathogen Mycobacterium tuberculosis (M.tb). The World Health Organization estimates that approximately eight to ten million new cases of TB occur each year worldwide, and the incidence of TB is currently increasing. Along with malaria and HIV-AIDS, TB is one of the top three causes of death from a single infectious agent, with approximately...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K39/04C12N9/10C12N9/16A61K39/00
CPCA61K2039/522C12N9/16A61K39/04C12N9/1051A61P31/04A61P31/06
Inventor N·卡勒维尔特A·巴特尼N·菲斯詹斯C·许根
Owner VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com